CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-20 | Cooke Shane Director | Grant or award · Restricted Stock Unit Award | +5,409 | 5,409 | ||
| 2026-05-20 | GAYNOR RICHARD Director | Grant or award · Non Qualified Stock Option (Right to Buy) | +11,538 | 11,538 | ||
| 2026-05-20 | GAYNOR RICHARD Director | Grant or award · Restricted Stock Unit Award | +5,409 | 5,409 | ||
| 2026-05-20 | Cooke Shane Director | Grant or award · Non Qualified Stock Option (Right to Buy) | +11,538 | 11,538 | ||
| 2026-05-20 | Cooke Shane Director | Grant or award · Restricted Stock Unit Award | +5,409 | 5,409 | ||
| 2026-05-04 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $33.20 | $68K | 231,558 |
| 2026-05-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 90,389 |
| 2026-05-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,000 | $33.40 | $301K | 81,389 |
| 2026-05-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 11,356 | ||
| 2026-04-11 | Lurker Nancy Director | Option exercise | +3,751 | 14,456 | ||
| 2026-04-11 | Lurker Nancy Director | Shares withheld for taxes | −901 | $33.36 | $30K | 13,555 |
| 2026-04-11 | Lurker Nancy Director | Option exercise · Restricted Stock Unit Award | −3,751 | 3,752 | ||
| 2026-04-06 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $34.57 | $70K | 233,592 |
| 2026-04-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 94,389 |
| 2026-04-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,000 | $35.51 | $320K | 85,389 |
| 2026-04-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 16,356 | ||
| 2026-03-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $29.76 | $61K | 235,626 |
| 2026-03-02 | Reed Joshua SVP, Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +66,430 | 66,430 | ||
| 2026-03-02 | Reed Joshua SVP, Chief Financial Officer | Grant or award · Restricted Stock Unit Award | +30,854 | 30,854 | ||
| 2026-03-02 | POPS RICHARD F Director and CEO, Alkermes plc | Grant or award · Restricted Stock Unit Award | +88,843 | 88,843 |
Page 5 of 41 · 804 trades